Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

被引：1134

作者：

Dai, Wenhao ^{[1
,2
]}

Zhang, Bing ^{[3
,4
]}

Jiang, Xia-Ming ^{[5
]}

Su, Haixia ^{[1
,6
]}

Li, Jian ^{[1
,6
]}

Zhao, Yao ^{[3
,4
]}

Xie, Xiong ^{[1
,6
]}

Jin, Zhenming ^{[3
,4
]}

Peng, Jingjing ^{[1
,6
]}

Liu, Fengjiang ^{[3
,4
]}

Li, Chunpu ^{[1
,6
]}

Li, You ^{[8
]}

Bai, Fang ^{[3
,4
]}

Wang, Haofeng ^{[3
,4
]}

Cheng, Xi ^{[1
]}

Cen, Xiaobo ^{[8
]}

Hu, Shulei ^{[1
]}

Yang, Xiuna ^{[3
,4
]}

Wang, Jiang ^{[1
,6
]}

Liu, Xiang ^{[9
]}

Xiao, Gengfu ^{[5
]}

Jiang, Hualiang ^{[1
,3
,4
,6
]}

Rao, Zihe ^{[3
,4
]}

Zhang, Lei-Ke ^{[5
]}

Xu, Yechun ^{[1
,6
]}

Yang, Haitao ^{[3
,4
]}

Liu, Hong ^{[1
,2
,6
,7
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[2] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Jiangsu, Peoples R China

[3] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China

[4] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[5] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China

[6] Univ Chinese Acad Sci, Beijing 100049, Peoples R China

[7] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China

[8] Sichuan Univ, Westchina Hosp, Natl Chengdu Ctr Safety Evaluat Drugs, Chengdu 610041, Sichuan, Peoples R China

[9] Nankai Univ, State Key Lab Med Chem Biol, Frontiers Sci Ctr Cell Response, Coll Pharm,Coll Life Sci, Tianjin 300353, Peoples R China

来源：

SCIENCE | 2020年 / 368卷 / 6497期

基金：

中国国家自然科学基金;

关键词：

CORONAVIRUS; INHIBITORS; 3C;

D O I：

10.1126/science.abb4489

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main protease of SARS-CoV-2, M-pro, is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M-pro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The x-ray crystal structures of SARS-CoV-2 M-pro in complex with 11a or 11b, both determined at a resolution of 1.5 angstroms, showed that the aldehyde groups of 11a and 11b are covalently bound to cysteine 145 of M-pro. Both compounds showed good pharmacokinetic properties in vivo, and 11a also exhibited low toxicity, which suggests that these compounds are promising drug candidates.

引用

页码：1331 / +

页数：35

共 50 条

[1] Views on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al. (2020)
Odhar, Hasanain Abdulhameed
BIOINFORMATION, 2020, 16 (05) : 435 - 435
[2] Comments on Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease by Dai et al. (2020)
Chiappelli, Francesco
BIOINFORMATION, 2020, 16 (05) : 432 - 433
[3] Research Progress of Antiviral Drug Targeting the Main Protease of SARS-CoV-2
Wang, Chunxia
Hu, Xiaodong
Xu, Bin
Cao, Chunyang
CHINESE JOURNAL OF ORGANIC CHEMISTRY, 2022, 42 (07) : 1974 - 1999
[4] Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
Johansen-Leete, Jason
Ullrich, Sven
Fry, Sarah E.
Frkic, Rebecca
Bedding, Max J.
Aggarwal, Anupriya
Ashhurst, Anneliese S.
Ekanayake, Kasuni B.
Mahawaththa, Mithun C.
Sasi, Vishnu M.
Luedtke, Stephanie
Ford, Daniel J.
O'Donoghue, Anthony J.
Passioura, Toby
Larance, Mark
Otting, Gottfried
Turville, Stuart
Jackson, Colin J.
Nitsche, Christoph
Payne, Richard J.
CHEMICAL SCIENCE, 2022, 13 (13) : 3826 - 3836
[5] Drug development targeting SARS-CoV-2 main protease
Bulut, Haydar
GLOBAL HEALTH & MEDICINE, 2022, 4 (06): : 296 - 300
[6] Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease
Kandeel, Mahmoud
Kim, Jinsoo
Fayez, Mahmoud
Kitade, Yukio
Kwon, Hyung-Joo
PEERJ, 2022, 10
[7] Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease
Sarkar, Arighna
Mandal, Kalyaneswar
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (44) : 23492 - 23494
[8] Structure-based identification of potential SARS-CoV-2 main protease inhibitors
Khan, Shama
Fakhar, Zeynab
Hussain, Afzal
Ahmad, Aijaz
Jairajpuri, Deeba Shamim
Alajmi, Mohamed F.
Hassan, Md. Imtaiyaz
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (08): : 3595 - 3608
[9] Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors
Maltarollo, Vinicius Goncalves
da Silva, Elany Barbosa
Kronenberger, Thales
Andrade, Marina Mol Sena
Marques, Gabriel V. de Lima
Oliveira, Nereu J. Candido
Santos, Lucianna H.
Rezende Junior, Celso de Oliveira
Martinho, Ana C. Cassiano
Skinner, Danielle
Fajtova, Pavla
Fernandes, Thais H.
dos Santos, Eduardo da Silveira
Gazolla, Poliana A. Rodrigues
de Souza, Ana P. Martins
da Silva, Milene Lopes
dos Santos, Fabiola S.
Lavorato, Stefania N.
Bretas, Ana C. Oliveira
Carvalho, Diogo Teixeira
Franco, Lucas Lopardi
Luedtke, Stephanie
Giardini, Miriam A.
Poso, Antti
Dias, Luiz C.
Podust, Larissa M.
Alves, Ricardo J.
McKerrow, James
Andrade, Saulo F.
Teixeira, Robson R.
Siqueira-Neto, Jair L.
O'Donoghue, Anthony
de Oliveira, Renata B.
Ferreira, Rafaela S.
FUTURE MEDICINAL CHEMISTRY, 2023, 15 (11) : 959 - 985
[10] In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
Wen, Lei
Tang, Kaiming
Chik, Kenn Ka-Heng
Chan, Chris Chun-Yiu
Tsang, Jessica Oi-Ling
Liang, Ronghui
Cao, Jianli
Huang, Yaoqiang
Luo, Cuiting
Cai, Jian-Piao
Ye, Zi-Wei
Yin, Feifei
Chu, Hin
Jin, Dong-Yan
Yuen, Kwok-Yung
Yuan, Shuofeng
Chan, Jasper Fuk-Woo
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (06): : 1555 - 1564

← 1 2 3 4 5 →